Arvinas Launched First Human Trial for HPK1 Degrader
The drug candidate ARV-6723 has entered Phase 1/2 clinical testing for patients with advanced solid tumors.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Would you consider participating in an experimental clinical trial for a cancer treatment?
Arvinas has initiated a Phase 1/2 clinical trial, known as ARV-6723-101, to evaluate the safety and efficacy of its oral PROTAC drug candidate ARV-6723 in humans. This represents the first immuno-oncology candidate from the company to reach clinical trials.
Why it matters
HPK1 serves as a negative regulator of immune cell activation, and targeting it could potentially overcome resistance to existing immune checkpoint inhibitors. The trial now moves this research from preclinical models into patient assessment to determine if HPK1 degradation can drive antitumor effects.
ARV-6723 functions as an oral PROTAC—a proteolysis-targeting chimera designed to trigger the degradation of the HPK1 protein. The study assesses this degradation as a monotherapy and in combination with pembrolizumab across patients with advanced solid tumors.
The players
Arvinas
A biotechnology company specializing in PROTAC protein degradation technology for the treatment of oncology and other diseases.
The details
HPK1 (hematopoietic progenitor kinase 1) acts as a negative regulator, a protein that suppresses immune activation, within T cells, B cells, natural killer cells, and dendritic cells. By degrading this protein, the drug aims to remove a brake on the immune system, thereby altering the tumor microenvironment. The trial assesses safety, pharmacokinetics, and pharmacodynamics before evaluating antitumor activity in combination with anti-PD-1 therapy.
Timeline
September 28, 2026: Arvinas dosed the first patient in the clinical trial.
The Tech Race
This development follows the established paradigm of immune checkpoint inhibitors by attempting to remove intracellular suppressors of immune function. It represents a move beyond traditional monoclonal antibodies toward targeted protein degradation within the immuno-oncology field.
The clinical trial is currently enrolling patients with advanced solid tumors to assess the drug's safety and preliminary antitumor activity. Future availability remains dependent on these initial Phase 1/2 results and subsequent regulatory approval processes.
The takeaway
The clinical trial is testing whether deep HPK1 degradation translates into meaningful clinical outcomes for patients with solid tumors. Observers should track the study, registered under NCT07749586, for future updates on preliminary antitumor activity and safety data.
Further reading
For more on the latest research and clinical developments in this field, visit the Biotech section.
Live Poll
Would you consider participating in an experimental clinical trial for a cancer treatment?
